Increased biologic utilization in Latino patients with psoriasis
Introduction Hispanic/Latino populations are more likely to have extensive psoriasis than the non-Hispanic/Latino population. Biologics are indicated for moderate/severe psoriasis or psoriasis with comorbidities. No studies have assessed ethnicity as a predictor of biologic utilization. We aimed to...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-02-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2020.1793889 |
| _version_ | 1797683565150863360 |
|---|---|
| author | Tammy Gonzalez Alan B. Fleischer |
| author_facet | Tammy Gonzalez Alan B. Fleischer |
| author_sort | Tammy Gonzalez |
| collection | DOAJ |
| description | Introduction Hispanic/Latino populations are more likely to have extensive psoriasis than the non-Hispanic/Latino population. Biologics are indicated for moderate/severe psoriasis or psoriasis with comorbidities. No studies have assessed ethnicity as a predictor of biologic utilization. We aimed to determine if biologic utilization differs between Latinos and non-Latinos with psoriasis. Methods This study utilizes data from the National Ambulatory Medical Care Survey (NAMCS) from 2003 to 2016. Psoriasis visits were selected by International Classification of Diseases, Ninth or Tenth Revision (ICD-9/ICD-10) classification. The primary outcome is biologic use at the time of visit. Results Of 1202 psoriasis visits, Latinos consisted of 9.7% (95% Confidence Interval 7.3–12) of the study population and 65% (95%CI 61–69) used private insurance. Multivariate analysis reveals the increased likelihood of biologic utilization in Latinos compared to non-Latinos (Odds Ratio (OR) 2.4, 95% CI 1.1–5.4, p = .03). Independently, private insurance status is associated with increased biologic use compared to public insurance (OR 2.4, 95% CI 1.2–5.0, p = .02). Private insurance status did not differ between Latinos and non-Latinos with psoriasis (OR 1.0, 95% CI 0.5–1.9, p = .98). Conclusions Hispanic/Latino ethnicity and private insurance status are independent predictors of biologic utilization, suggesting that biologic mechanisms may influence the increased use of biologics in Latinos with psoriasis. |
| first_indexed | 2024-03-12T00:17:11Z |
| format | Article |
| id | doaj.art-9d1d4dcf1fd04dbc9f26ad8b1346e293 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:17:11Z |
| publishDate | 2022-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-9d1d4dcf1fd04dbc9f26ad8b1346e2932023-09-15T14:23:07ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-02-0133296596810.1080/09546634.2020.17938891793889Increased biologic utilization in Latino patients with psoriasisTammy Gonzalez0Alan B. Fleischer1Department of Dermatology, University of Cincinnati School of MedicineDepartment of Dermatology, University of Cincinnati School of MedicineIntroduction Hispanic/Latino populations are more likely to have extensive psoriasis than the non-Hispanic/Latino population. Biologics are indicated for moderate/severe psoriasis or psoriasis with comorbidities. No studies have assessed ethnicity as a predictor of biologic utilization. We aimed to determine if biologic utilization differs between Latinos and non-Latinos with psoriasis. Methods This study utilizes data from the National Ambulatory Medical Care Survey (NAMCS) from 2003 to 2016. Psoriasis visits were selected by International Classification of Diseases, Ninth or Tenth Revision (ICD-9/ICD-10) classification. The primary outcome is biologic use at the time of visit. Results Of 1202 psoriasis visits, Latinos consisted of 9.7% (95% Confidence Interval 7.3–12) of the study population and 65% (95%CI 61–69) used private insurance. Multivariate analysis reveals the increased likelihood of biologic utilization in Latinos compared to non-Latinos (Odds Ratio (OR) 2.4, 95% CI 1.1–5.4, p = .03). Independently, private insurance status is associated with increased biologic use compared to public insurance (OR 2.4, 95% CI 1.2–5.0, p = .02). Private insurance status did not differ between Latinos and non-Latinos with psoriasis (OR 1.0, 95% CI 0.5–1.9, p = .98). Conclusions Hispanic/Latino ethnicity and private insurance status are independent predictors of biologic utilization, suggesting that biologic mechanisms may influence the increased use of biologics in Latinos with psoriasis.http://dx.doi.org/10.1080/09546634.2020.1793889psoriasisbiologicshispaniclatino |
| spellingShingle | Tammy Gonzalez Alan B. Fleischer Increased biologic utilization in Latino patients with psoriasis Journal of Dermatological Treatment psoriasis biologics hispanic latino |
| title | Increased biologic utilization in Latino patients with psoriasis |
| title_full | Increased biologic utilization in Latino patients with psoriasis |
| title_fullStr | Increased biologic utilization in Latino patients with psoriasis |
| title_full_unstemmed | Increased biologic utilization in Latino patients with psoriasis |
| title_short | Increased biologic utilization in Latino patients with psoriasis |
| title_sort | increased biologic utilization in latino patients with psoriasis |
| topic | psoriasis biologics hispanic latino |
| url | http://dx.doi.org/10.1080/09546634.2020.1793889 |
| work_keys_str_mv | AT tammygonzalez increasedbiologicutilizationinlatinopatientswithpsoriasis AT alanbfleischer increasedbiologicutilizationinlatinopatientswithpsoriasis |